| Outcome Measures: |
Primary: Incidence of TLC-6740 treatment-emergent adverse events, Adverse events (AEs) - severity of the AEs will be graded using the Common Terminology Criteria for AE (CTCAE) (v5.0). The relationship between AEs and the study drug will be indicated as related or not related., Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 87 (Parts F, G) of the study|PK of TLC-6740 AUC, Area under the concentration-time curve, Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 87 (Parts F, G) of the study|PK of TLC-6740 Cmax, Maximum plasma concentration, Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 87 (Parts F, G) of the study|PK of TLC-6740 tmax, Time to reach Cmax, Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 87 (Parts F, G) of the study|PK of TLC-6740 t1/2, Half-life, Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 87 (Parts F, G) of the study|PK of TLC-6740 CL/F, Apparent clearance, calculated as dose/AUC0-inf, Through study completion: up to Day 15 (Parts A, C); Day 24 (Parts B, C); Day 22 (Part D); Day 49 (Part E); Day 87 (Parts F, G) of the study |
|
